Novo Holdings A/S Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001388325
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 27 positions · Total reported value $1.55B · Top-10 concentration 73.2% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 40.7% · 2 new · 8 cut · 1 exited
Active Share (vs S&P 500): 99.7% · vs QQQ: 99.3% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -12.9% · vs SPY -15.1% · Prev Value $1.72B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -0.6% · vs SPY -2.8% · Latest Value $1.49B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2025 13F filing, Novo Holdings A/S disclosed 27 equity positions with a combined reported value of $1.55B. The filing implies a focused portfolio: its ten largest positions account for 73.2% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were VTI ($340.82M), BN ($159.85M), ASML ($141.18M). By sector, the heaviest allocations are Health Care 40.0%, Technology 14.3%. Versus the prior quarter, allocation shifted toward Health Care (+1.7pp) and away from Technology (-1.6pp).
Versus the prior quarter, Novo Holdings A/S opened 2 new positions, trimmed 8 and fully exited 1, a turnover rate of 40.7% of positions. The portfolio's overlap with the prior quarter was 87% of names.
The largest new positions opened in Q3 2025 were BBOT ($22.71M).
Of the 1 positions fully exited versus the prior quarter, the largest were BPMC ($33.96M), CBLL ($16.86M), ABCL ($2.24M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- BBOT BRIDGEBIO ONCOLOGY THERAPEUT · $22.71M
Insider Transactions (Form 4)
Latest Novo Holdings A/S buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-04 | Conversion | Hemab Therapeutics Holdings, Inc. | 4,180,550 | — | SEC filing |
| 2026-05-01 | Buy | Avalyn Pharma Inc. | 555,555 | $18.00 | SEC filing |
| 2026-05-01 | Conversion | Avalyn Pharma Inc. | 3,327,734 | — | SEC filing |
Fund Profile
Novo Holdings A/S files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 26 positions worth $1.49B in total. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Portfolio Structure
- 26 positions · $1.49B reported value (Q3 2026)
- Top 10 holdings = 76.1% of reported value
- Largest position: EWTX (EDGEWISE THERAPEUTICS INC) at 14.6%
- Average position size: $57.30M
Sector Tilt
- Health Care 67.0%
- Information Technology 17.7%
- Real Estate 10.9%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 2 new, 6 added, 8 reduced, 1 exited
- 10 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.04M | $340.82M | 21.97% | Hold | |
| 2 |
|
2.33M | $159.85M | 10.30% | Hold | |
| 3 |
|
145.84K | $141.18M | 9.10% | Reduce | |
| 4 |
|
1.26M | $92.67M | 5.97% | Reduce | |
| 5 |
|
5.35M | $86.78M | 5.59% | Hold | |
| 6 |
|
330.19K | $78.25M | 5.04% | Hold | |
| 7 |
|
750.00K | $70.61M | 4.55% | Hold | |
| 8 |
|
1.62M | $67.68M | 4.36% | Add | |
| 9 |
|
2.38M | $51.36M | 3.31% | Hold | |
| 10 |
|
257.33K | $45.99M | 2.96% | Reduce | |
| 11 |
|
2.00M | $44.40M | 2.86% | Reduce | |
| 12 |
|
1.75M | $43.66M | 2.81% | Add | |
| 13 |
|
7.93M | $38.70M | 2.49% | Reduce | |
| 14 |
|
1.94M | $35.83M | 2.31% | Add | |
| 15 |
|
660.00K | $35.75M | 2.30% | Hold | |
| 16 |
|
916.16K | $33.00M | 2.13% | Hold | |
| 17 |
|
1.20M | $31.04M | 2.00% | Hold | |
| 18 |
|
1.43M | $29.20M | 1.88% | Add | |
| 19 |
|
200.00K | $28.80M | 1.86% | Reduce | |
| 20 |
|
2.35M | $28.61M | 1.84% | Reduce | |
| 21 |
|
1.96M | $22.71M | 1.46% | New | |
| 22 |
|
500.00K | $19.86M | 1.28% | Add | |
| 23 |
|
2.00M | $17.38M | 1.12% | Hold | |
| 24 |
|
158.15K | $3.88M | 0.25% | Reduce | |
| 25 |
|
441.56K | $2.33M | 0.15% | Hold | |
| 26 |
|
2.51M | $912.27K | 0.06% | Reduce | |
| 27 |
|
86.58K | $322.07K | 0.02% | Reduce | |
FAQ
What did Novo Holdings A/S buy in 2025-Q3?
In its 2025-Q3 13F filing, Novo Holdings A/S reported 27 equity positions worth $1.55B in aggregate; its largest disclosed positions were VTI ($340.82M), BN ($159.85M), ASML ($141.18M).
How large is Novo Holdings A/S's portfolio?
Novo Holdings A/S reported $1.55B of long equity holdings across 27 positions as of 2025-Q3. Top-10 holdings account for 73.2% of reported value.
What is Novo Holdings A/S's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.